GENE ONLINE|News &
Jazz Pharmaceuticals Announces $1 Billion Acquisition of Chimerix to Advance Brain Cancer Treatment
In a strategic move to bolster its oncology portfolio, Jazz Pharmaceuticals has announced the acquisition of Chimerix, a biopharmaceutical company specializing in innovative cancer therapies. The deal, valued at nearly $1 billion, includes Chimerix’s experimental brain cancer drug, dordaviprone.
The acquisition underscores Jazz Pharmaceuticals’ commitment to addressing unmet medical needs in oncology. Dordaviprone, currently under development by Chimerix, is designed to target aggressive forms of brain cancer and represents a promising addition to Jazz’s pipeline of treatments.
This transaction marks a significant milestone for both companies. Jazz Pharmaceuticals aims to leverage its expertise and resources to accelerate the clinical development and potential commercialization of dordaviprone. Meanwhile, Chimerix gains the opportunity to expand the reach and impact of its groundbreaking research through Jazz’s global infrastructure.
Date: March 5, 2025
Newsflash | Powered by GeneOnline AI
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
